A new CBD derivative (HU-444) reduced arthritis inflammation in mice without any psychoactive effects
HU-444, a novel CBD derivative that cannot convert to THC, demonstrated potent anti-inflammatory activity in arthritis models and suppressed liver damage without causing cannabis-like effects.
Quick Facts
What This Study Found
Researchers synthesized HU-444, a novel derivative of CBD designed to be structurally incapable of converting to THC in acidic conditions (a potential concern with natural CBD). The compound showed strong anti-inflammatory properties both in cell cultures and in living animals.
In laboratory tests, HU-444 reduced reactive oxygen species production and inhibited TNF-alpha (a key inflammatory molecule) production by macrophages. In mice, it suppressed TNF-alpha production, reduced liver damage from inflammation, and lowered the severity of collagen-induced arthritis (a standard rheumatoid arthritis model).
Importantly, HU-444 did not produce THC-like behavioral effects in mice, confirming its non-psychoactive profile. The researchers proposed it as a potential novel drug for rheumatoid arthritis and other inflammatory diseases.
Key Numbers
HU-444 structurally cannot cyclize to THC. Reduced TNF-alpha production in vitro. Ameliorated liver damage in vivo. Lowered collagen-induced arthritis severity. No THC-like behavioral effects.
How They Did This
Chemical synthesis and pharmacological evaluation. In vitro: reactive oxygen intermediates and TNF-alpha production in macrophages. In vivo: TNF-alpha suppression, liver damage model, and mouse collagen-induced arthritis model. Behavioral testing confirmed absence of THC-like effects.
Why This Research Matters
CBD has demonstrated anti-inflammatory potential, but its possible conversion to THC in acidic environments raised concerns. HU-444 eliminates this issue while retaining anti-inflammatory activity, potentially offering a cleaner pharmaceutical candidate for inflammatory diseases.
The Bigger Picture
Drug development from natural cannabinoids involves creating derivatives that maximize therapeutic effects while eliminating psychoactive or unwanted properties. HU-444 represents this approach applied to CBD, potentially bringing cannabinoid anti-inflammatory medicine closer to mainstream pharmaceutical acceptance.
What This Study Doesn't Tell Us
Preclinical study only, with no human data. Mouse arthritis models do not perfectly replicate human rheumatoid arthritis. The optimal dosing, long-term safety, and pharmacokinetics of HU-444 have not been established. Comparison to existing arthritis treatments was not made.
Questions This Raises
- ?Would HU-444 be effective in human arthritis?
- ?How does its efficacy compare to existing anti-inflammatory drugs?
- ?Could it be combined with current rheumatoid arthritis treatments?
Trust & Context
- Key Stat:
- HU-444: anti-inflammatory CBD derivative that cannot convert to THC
- Evidence Grade:
- Preclinical study with in vitro and in vivo evidence. Promising but no human clinical data.
- Study Age:
- Published in 2015. Clinical development status of HU-444 is not well-publicized.
- Original Title:
- HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.
- Published In:
- The Journal of pharmacology and experimental therapeutics, 355(1), 66-75 (2015)
- Authors:
- Haj, Christeene G, Sumariwalla, Percy F, Hanuš, Lumír(2), Kogan, Natalya M, Yektin, Zhana, Mechoulam, Raphael, Feldmann, Mark, Gallily, Ruth
- Database ID:
- RTHC-00974
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is HU-444?
It is a synthetic derivative of CBD designed so it cannot convert to THC. It retained CBD's anti-inflammatory properties and reduced arthritis severity in mice without producing any psychoactive effects.
Can CBD convert to THC?
Natural CBD can theoretically cyclize to THC under acidic conditions. HU-444 was specifically designed to make this conversion structurally impossible, addressing a safety concern for pharmaceutical development.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-arthritis-research
Cite This Study
https://rethinkthc.com/research/RTHC-00974APA
Haj, Christeene G; Sumariwalla, Percy F; Hanuš, Lumír; Kogan, Natalya M; Yektin, Zhana; Mechoulam, Raphael; Feldmann, Mark; Gallily, Ruth. (2015). HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.. The Journal of pharmacology and experimental therapeutics, 355(1), 66-75. https://doi.org/10.1124/jpet.115.226100
MLA
Haj, Christeene G, et al. "HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.." The Journal of pharmacology and experimental therapeutics, 2015. https://doi.org/10.1124/jpet.115.226100
RethinkTHC
RethinkTHC Research Database. "HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic C..." RTHC-00974. Retrieved from https://rethinkthc.com/research/haj-2015-hu444-a-novel-potent
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.